$Kinnate BioPharma Inc.(KNTE)$
A new pharmaceutical star or dust??[serious]
A biopharmaceutical company focused on the discovery and development of small molecules kinase inhibitors for difficult to treat, genomically defined cancers.
Listed on December 2020 only
Key ratio [Drowsy]
-basically the fundamental is still not solid with all the key ratio in bad numbers
-total debt to equity ratio 0.15
-negative fcf
Technical
-overall a down trend[Weak]
- short term wise rising trend with higher low value
-crossing above ema30 and 60 , approaching ema200[Put]
Next earning report in 15/8/2022
With all the past 6 quarters earning reports consecutively missed the estimate, will it continue the same or have a breakthrough?? [Doubt]
Surpassing the ema200 for first time ever since listed??[Thinking]
@Daily_Discussion@TigerPM@TigerStars@CaptainTiger
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Good